Cargando…

Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting

PURPOSE: The high‐dimensional propensity score (HDPS) is a semi‐automated procedure for confounder identification, prioritisation and adjustment in large healthcare databases that requires investigators to specify data dimensions, prioritisation strategy and tuning parameters. In practice, reporting...

Descripción completa

Detalles Bibliográficos
Autores principales: Tazare, John, Wyss, Richard, Franklin, Jessica M., Smeeth, Liam, Evans, Stephen J. W., Wang, Shirley V., Schneeweiss, Sebastian, Douglas, Ian J., Gagne, Joshua J., Williamson, Elizabeth J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305520/
https://www.ncbi.nlm.nih.gov/pubmed/35092316
http://dx.doi.org/10.1002/pds.5412
_version_ 1784752345602588672
author Tazare, John
Wyss, Richard
Franklin, Jessica M.
Smeeth, Liam
Evans, Stephen J. W.
Wang, Shirley V.
Schneeweiss, Sebastian
Douglas, Ian J.
Gagne, Joshua J.
Williamson, Elizabeth J.
author_facet Tazare, John
Wyss, Richard
Franklin, Jessica M.
Smeeth, Liam
Evans, Stephen J. W.
Wang, Shirley V.
Schneeweiss, Sebastian
Douglas, Ian J.
Gagne, Joshua J.
Williamson, Elizabeth J.
author_sort Tazare, John
collection PubMed
description PURPOSE: The high‐dimensional propensity score (HDPS) is a semi‐automated procedure for confounder identification, prioritisation and adjustment in large healthcare databases that requires investigators to specify data dimensions, prioritisation strategy and tuning parameters. In practice, reporting of these decisions is inconsistent and this can undermine the transparency, and reproducibility of results obtained. We illustrate reporting tools, graphical displays and sensitivity analyses to increase transparency and facilitate evaluation of the robustness of analyses involving HDPS. METHODS: Using a study from the UK Clinical Practice Research Datalink that implemented HDPS we demonstrate the application of the proposed recommendations. RESULTS: We identify seven considerations surrounding the implementation of HDPS, such as the identification of data dimensions, method for code prioritisation and number of variables selected. Graphical diagnostic tools include assessing the balance of key confounders before and after adjusting for empirically selected HDPS covariates and the identification of potentially influential covariates. Sensitivity analyses include varying the number of covariates selected and assessing the impact of covariates behaving empirically as instrumental variables. In our example, results were robust to both the number of covariates selected and the inclusion of potentially influential covariates. Furthermore, our HDPS models achieved good balance in key confounders. CONCLUSIONS: The data‐adaptive approach of HDPS and the resulting benefits have led to its popularity as a method for confounder adjustment in pharmacoepidemiological studies. Reporting of HDPS analyses in practice may be improved by the considerations and tools proposed here to increase the transparency and reproducibility of study results.
format Online
Article
Text
id pubmed-9305520
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-93055202022-07-28 Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting Tazare, John Wyss, Richard Franklin, Jessica M. Smeeth, Liam Evans, Stephen J. W. Wang, Shirley V. Schneeweiss, Sebastian Douglas, Ian J. Gagne, Joshua J. Williamson, Elizabeth J. Pharmacoepidemiol Drug Saf Original Articles PURPOSE: The high‐dimensional propensity score (HDPS) is a semi‐automated procedure for confounder identification, prioritisation and adjustment in large healthcare databases that requires investigators to specify data dimensions, prioritisation strategy and tuning parameters. In practice, reporting of these decisions is inconsistent and this can undermine the transparency, and reproducibility of results obtained. We illustrate reporting tools, graphical displays and sensitivity analyses to increase transparency and facilitate evaluation of the robustness of analyses involving HDPS. METHODS: Using a study from the UK Clinical Practice Research Datalink that implemented HDPS we demonstrate the application of the proposed recommendations. RESULTS: We identify seven considerations surrounding the implementation of HDPS, such as the identification of data dimensions, method for code prioritisation and number of variables selected. Graphical diagnostic tools include assessing the balance of key confounders before and after adjusting for empirically selected HDPS covariates and the identification of potentially influential covariates. Sensitivity analyses include varying the number of covariates selected and assessing the impact of covariates behaving empirically as instrumental variables. In our example, results were robust to both the number of covariates selected and the inclusion of potentially influential covariates. Furthermore, our HDPS models achieved good balance in key confounders. CONCLUSIONS: The data‐adaptive approach of HDPS and the resulting benefits have led to its popularity as a method for confounder adjustment in pharmacoepidemiological studies. Reporting of HDPS analyses in practice may be improved by the considerations and tools proposed here to increase the transparency and reproducibility of study results. John Wiley & Sons, Inc. 2022-02-12 2022-04 /pmc/articles/PMC9305520/ /pubmed/35092316 http://dx.doi.org/10.1002/pds.5412 Text en © 2022 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Tazare, John
Wyss, Richard
Franklin, Jessica M.
Smeeth, Liam
Evans, Stephen J. W.
Wang, Shirley V.
Schneeweiss, Sebastian
Douglas, Ian J.
Gagne, Joshua J.
Williamson, Elizabeth J.
Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting
title Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting
title_full Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting
title_fullStr Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting
title_full_unstemmed Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting
title_short Transparency of high‐dimensional propensity score analyses: Guidance for diagnostics and reporting
title_sort transparency of high‐dimensional propensity score analyses: guidance for diagnostics and reporting
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305520/
https://www.ncbi.nlm.nih.gov/pubmed/35092316
http://dx.doi.org/10.1002/pds.5412
work_keys_str_mv AT tazarejohn transparencyofhighdimensionalpropensityscoreanalysesguidancefordiagnosticsandreporting
AT wyssrichard transparencyofhighdimensionalpropensityscoreanalysesguidancefordiagnosticsandreporting
AT franklinjessicam transparencyofhighdimensionalpropensityscoreanalysesguidancefordiagnosticsandreporting
AT smeethliam transparencyofhighdimensionalpropensityscoreanalysesguidancefordiagnosticsandreporting
AT evansstephenjw transparencyofhighdimensionalpropensityscoreanalysesguidancefordiagnosticsandreporting
AT wangshirleyv transparencyofhighdimensionalpropensityscoreanalysesguidancefordiagnosticsandreporting
AT schneeweisssebastian transparencyofhighdimensionalpropensityscoreanalysesguidancefordiagnosticsandreporting
AT douglasianj transparencyofhighdimensionalpropensityscoreanalysesguidancefordiagnosticsandreporting
AT gagnejoshuaj transparencyofhighdimensionalpropensityscoreanalysesguidancefordiagnosticsandreporting
AT williamsonelizabethj transparencyofhighdimensionalpropensityscoreanalysesguidancefordiagnosticsandreporting